An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Coherus BioSciences Announces New Employment Inducement Grants
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Coherus BioSciences grants options to newly hired employees
Positive
Coherus BioSciences has granted options to purchase 187,000 shares of common stock to newly hired employees. The per share exercise price is $4.17, the closing trading price on the grant date. One Senior Vice President level executive was granted options to purchase 100,000 shares, while five additional non-officer employees were granted options to purchase a total of 87,000 shares.
Negative
None.
REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 187,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.17, the closing trading price on the grant date. One Senior Vice President level executive was granted options to purchase 100,000 shares; and five additional non-officer employees were granted options to purchase an aggregate of 87,000 shares.
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Coherus BioSciences Contact Information:
IR Contact Marek Ciszewski Coherus BioSciences, Inc. IR@coherus.com
FAQ
What did Coherus BioSciences announce?
Coherus BioSciences announced that they have granted options to purchase shares of common stock to newly hired employees.
How many shares were granted?
A total of 187,000 shares were granted.
What is the exercise price per share?
The exercise price per share is $4.17.
Who received the options?
One Senior Vice President level executive received options to purchase 100,000 shares, while five additional non-officer employees received options to purchase a total of 87,000 shares.
What is the purpose of the options?
The options were granted to induce new employees to enter into employment with the Company.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
